Male Sexual Health — Cost, Top Hospitals & Success Rates | MyMedicPlus

Male sexual health encompasses the physical, psychological, hormonal, and relational aspects of men's sexual function and wellbeing. Sexual health problems are highly prevalent yet significantly under-reported due to stigma — it is estimated that fewer than 25% of men with erectile dysfunction (ED) seek professional help. Proactive identification and evidence-based treatment of male sexual dysfunction can dramatically improve quality of life, relationship satisfaction, and — in the case of ED — cardiovascular risk management.

The male sexual response involves sequential phases: desire (libido), arousal (penile erection mediated by nitric oxide-dependent smooth muscle relaxation), emission (seminal vesicle and vas deferens contraction), and ejaculation (coordinated pelvic floor muscle contraction expelling seminal fluid). Disorders can affect any phase: desire disorders (low libido, HSDD), erection disorders (ED), ejaculation disorders (premature ejaculation, delayed ejaculation, anejaculation, retrograde ejaculation), and orgasmic disorders.

Erectile dysfunction (ED) — the inability to achieve or maintain an erection sufficient for satisfactory sexual performance — affects approximately 52% of men aged 40–70, rising sharply with age. It is classified as psychogenic, vasculogenic, neurogenic, hormonal, or mixed. Critically, ED is now recognised as a cardiovascular sentinel event: men presenting with ED have a 2–3-fold increased risk of cardiovascular events within 10 years, and endothelial dysfunction underlies both conditions.

The Massachusetts Male Aging Study (MMAS) — the landmark epidemiological study — demonstrated a strong association between ED and modifiable cardiovascular risk factors: hypertension, dyslipidaemia, diabetes, and smoking. This has shifted the paradigm: a man presenting with ED should receive a full cardiovascular risk assessment, not just a PDE5 inhibitor prescription.

Male sexual health services address:

• Erectile Dysfunction (ED): The most common male sexual complaint. Vasculogenic ED (endothelial dysfunction, atherosclerosis) is the most prevalent aetiology; psychogenic ED is common in younger men; neurogenic ED follows pelvic surgery, diabetes, or spinal cord injury; hormonal ED is caused by hypogonadism or hyperprolactinaemia.
• Premature Ejaculation (PE): Defined by the ISSM as ejaculation that always or nearly always occurs within 1 minute of vaginal penetration, with inability to delay, and causing distress. Affects 20–30% of men. Primary (lifelong) PE has a neurobiological serotonin basis; secondary PE is often acquired from ED or relationship factors.
• Low Testosterone (Male Hypogonadism): Testosterone deficiency causing low libido, ED, fatigue, depressed mood, reduced muscle mass, and increased adiposity. Confirmed by morning total testosterone <300 ng/dL on two occasions. Requires differentiation of primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism.
• Peyronie's Disease: Penile fibrosis causing curved, shortened, or indented erections, painful erections, and ED. Incidence approximately 9% in adult men. FDA-approved collagenase clostridium histolyticum (Xiaflex) is the first non-surgical treatment.
• Delayed Ejaculation / Anejaculation: Inability to ejaculate despite adequate stimulation. Commonly medication-induced (SSRIs, antihypertensives) or neurogenic.
• Male sexual pain: Dysorgasmia (painful orgasm), orchialgia, and prostatitis-related sexual pain are underrecognised conditions warranting assessment.

Men of any age experiencing sexual health concerns should seek assessment. Conditions warranting prompt referral include:

• Persistent ED lasting >3 months (even in young men — vascular causes must be excluded)
• Any ED in men with cardiovascular risk factors: hypertension, diabetes, hypercholesterolaemia, smoking, obesity
• Consistent ejaculation within 1 minute of penetration with associated distress
• Inability to ejaculate despite adequate stimulation (delayed ejaculation, anejaculation)
• Penile curvature, pain on erection, or palpable penile plaque (Peyronie's disease)
• Symptoms of low testosterone: low libido, fatigue, low mood, reduced muscle mass, poor concentration, hot flushes
• Sexual dysfunction following pelvic surgery (prostatectomy, cystectomy, rectal surgery) or radiotherapy
• Infertility investigation requiring semen analysis specimen production difficulties

Assessment includes a detailed sexual and medical history, International Index of Erectile Function (IIEF-5) questionnaire, physical examination including testicular palpation and penile inspection, fasting blood tests (testosterone, LH, FSH, prolactin, PSA, fasting glucose, HbA1c, lipids, FBC), and in selected cases: penile duplex Doppler ultrasound, nocturnal penile tumescence testing, or neurophysiological studies.

Treatment is matched to aetiology and patient preference:

Erectile Dysfunction:

• PDE5 inhibitors: First-line pharmacotherapy for ED. Sildenafil (Viagra, 25–100 mg on demand), tadalafil (Cialis, 5 mg daily or 10–20 mg on demand), vardenafil (Levitra), and avanafil (Stendra). Enhance nitric oxide-mediated smooth muscle relaxation with sexual stimulation. Contraindicated with nitrates. Success rates: 65–80% across ED aetiologies.
• Intracavernosal injection (ICI) therapy: Alprostadil (prostaglandin E1) injected directly into the corpora cavernosa. Highly effective (85–90% erection rates), bypassing PDE5 pathway. Used when oral therapy fails. Trimix (alprostadil + papaverine + phentolamine) provides enhanced response. Self-injection technique taught by clinic nurse.
• Vacuum erection device (VED): Non-pharmacological device creating negative pressure to draw blood into the penis, maintained with a constriction ring. Effective, low-risk, and without drug interactions. Useful after prostatectomy for penile rehabilitation.
• Penile prosthesis (implant): Surgical inflatable or malleable device for ED refractory to all other treatments. Three-piece inflatable prosthesis provides the most natural erection quality. Patient satisfaction rates exceed 90%. Permanent solution.

Premature Ejaculation:

• Dapoxetine (Priligy): FDA-approved short-acting SSRI taken 1–3 hours before sex. Increases intra-vaginal ejaculatory latency time (IELT) 2–4-fold. Most effective pharmacotherapy for PE.
• Topical anaesthetics: EMLA cream or lidocaine spray applied to the glans reduces sensitivity. Effective but may reduce pleasure for both partners.
• Behavioural techniques: Stop-start (Semans technique) and squeeze technique; pelvic floor physiotherapy for PE. Effective for acquired and situational PE.

Low Testosterone: Testosterone replacement therapy (TRT) in multiple formulations — gel, injection, patch, pellet. Restores serum testosterone to the mid-normal range; improves libido, ED, energy, and mood.

Peyronie's Disease: Collagenase clostridium histolyticum (Xiaflex) injections; penile traction therapy; surgical correction (plication, grafting) for stable disease.

Male sexual health treatment offers transformative benefits:

• Restored erectile function: PDE5 inhibitors restore satisfactory erections in 65–80% of men with ED. ICI therapy achieves erections in over 85% of PDE5 non-responders. Penile prosthesis provides a reliable permanent solution with >90% patient satisfaction.
• Cardiovascular risk identification: Evaluating ED triggers comprehensive cardiovascular risk assessment, identifying hypertension, dyslipidaemia, and diabetes that can be treated, potentially preventing future cardiac events.
• Improved relationship quality: Effective treatment of ED or PE reduces relationship stress, communication avoidance, and partner distress — improving intimacy and overall relationship satisfaction for both partners.
• Mood and energy restoration (TRT): Testosterone replacement improves fatigue, mood, cognitive function, and body composition in genuinely hypogonadal men, beyond its effects on libido and erection.
• PE treatment outcomes: Dapoxetine increases IELT from a mean of <1 minute to 2–4 minutes; combined with behavioural therapy, most men achieve clinically meaningful control and reduced distress.
• Fertility benefit: Treating ED, ejaculatory disorders, or hypogonadism may restore natural fertility in couples previously requiring assisted reproduction.

Male sexual health treatments carry specific risk profiles:

• PDE5 inhibitors: Absolute contraindication with organic nitrates (nitroglycerin, isosorbide) due to life-threatening hypotension. Common side effects: headache (15–25%), flushing, nasal congestion, dyspepsia, transient visual changes (blue-tinged vision with sildenafil). Rare: non-arteritic anterior ischaemic optic neuropathy (NAION) — men with prior NAION or disc at risk should avoid sildenafil/vardenafil. Priapism (prolonged erection >4 hours) requires emergency treatment.
• Intracavernosal injection: Priapism is the most serious risk (1–5% with alprostadil) requiring emergency penile aspiration or phenylephrine injection. Pain at injection site; penile fibrosis with long-term use. Syncope.
• Testosterone replacement: Polycythaemia (haematocrit >54% requires dose reduction or phlebotomy); acne; mood changes; sleep apnoea worsening; reduced testicular volume and suppression of spermatogenesis; prostate stimulation (PSA monitoring). Cardiovascular safety is under active investigation — recent large RCTs (TRAVERSE trial) show non-inferior cardiovascular outcomes vs placebo.
• Penile prosthesis: Infection (1–3%) potentially requiring device removal; mechanical failure (requires revision in 5–10% at 10 years); irreversible — natural erection function is permanently eliminated after implantation.
• Dapoxetine: Syncope risk — must be taken seated; contraindicated with MAOIs, thioridazine. Common side effects: nausea, headache, dizziness.

Structured follow-up ensures safety and optimises outcomes:

• ED treatment review (4–8 weeks): Assess IIEF-5 score change, medication tolerability, partner satisfaction, and cardiovascular risk factors. Optimise PDE5 inhibitor dose or switch to ICI if oral therapy ineffective.
• Testosterone replacement (3 months): Serum testosterone (morning, fasting), haematocrit, PSA. Confirm testosterone in mid-normal range (400–700 ng/dL). Adjust formulation or dose. Annual prostate health assessment including digital rectal examination.
• PE treatment review (4 weeks): Record IELT change, distress scores, partner feedback. Combine pharmacotherapy with pelvic floor physiotherapy for optimal outcomes.
• Post-prostatectomy rehabilitation: Penile rehabilitation protocol with daily PDE5 inhibitor and VED from 4 weeks post-surgery to preserve penile length and oxygenation during nerve recovery. Most erectile recovery occurs 12–24 months after nerve-sparing prostatectomy.
• Long-term cardiovascular monitoring: Men with vasculogenic ED require annual cardiovascular risk review — blood pressure, lipids, HbA1c, and ECG where indicated. Exercise testing may be performed before resuming sexual activity in men with known coronary artery disease.

Male sexual health treatment costs vary widely by modality and country:

• PDE5 inhibitors: Generic sildenafil is now widely available: GBP 1–5 per tablet (UK); USD 5–30 per tablet brand-name in USA, with generics from USD 1–2. Tadalafil daily (5 mg): approximately GBP 25/month generic in UK; USD 30–50/month generic in USA.
• Intracavernosal injection: Alprostadil (Caverject): approximately USD 70–200 per injection kit in USA. Trimix compounded: USD 20–60 per vial. Initial training visit and prescription required.
• Testosterone replacement (NHS): Covered for confirmed hypogonadism in the UK on NHS. Private endocrinology consultation: GBP 200–400. Annual hormone monitoring. USA: insurance-covered for clinical hypogonadism; gel USD 100–200/month brand-name.
• Penile prosthesis: Surgery costs USD 15,000–30,000 in the USA; GBP 10,000–20,000 UK private. In India, inflatable penile prosthesis surgery is available for approximately USD 4,000–8,000 at high-volume urological centres.
• Psychosexual therapy: Private sessions: GBP 80–150 (UK), USD 100–250 (USA) per session. Course of 8–12 sessions typical.

Modifiable lifestyle factors substantially influence male sexual health:

• Cardiovascular lifestyle optimisation: Regular aerobic exercise (150 minutes/week) improves endothelial function and testosterone levels. A Mediterranean diet reduces ED risk. Weight loss in obese men (BMI >30) can improve erectile function significantly — each unit of BMI reduction associated with 0.6-point IIEF improvement.
• Smoking cessation: Smoking causes endothelial dysfunction and is a major independent risk factor for ED. Cessation improves erectile function within 1–2 years. Nicotine replacement and varenicline are both supported.
• Alcohol reduction: Chronic heavy alcohol consumption causes hypogonadism and peripheral neuropathy contributing to ED. Moderate alcohol (<14 units/week) has minimal impact; heavy use significantly worsens sexual function.
• Pelvic floor exercises: A randomised trial demonstrated that pelvic floor muscle training achieved comparable ED improvement to sildenafil in mild-moderate ED at 3 months. Specifically targeting the ischiocavernosus and bulbocavernosus muscles — 3 sets of 10 contractions daily — is a safe, free intervention.
• Sleep and stress management: Treating obstructive sleep apnoea restores nocturnal testosterone secretion and often improves ED and libido. Stress reduction through mindfulness and adequate sleep supports healthy testosterone levels.